Abstracts tagged "Cardiovascular disease"

Abstract Number: L04 • 2019 ACR/ARP Annual Meeting
Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease
Maaman Bashir¹, Katherine Sherman ², Sara K. Tedeschi ³ and Ann Rosenthal ¹, ¹Medical College of Wisconsin, Milwaukee, ²Milwaukee VAMC, Milwaukee, ³Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from precipitation of calcium pyrophosphate (CPP) crystals in joints. Prior studies demonstrated that vascular calcification is more common…
Abstract Number: 182 • 2019 ACR/ARP Annual Meeting
Comparing the Generalizability of Cardiovascular Risk in Different Rheumatoid Arthritis Cohorts
Fenglong Xie ¹, Cynthia Crowson ², Iris Navarro-Millan ³, Monika Safford ³ and Jeffrey Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, ²Mayo Clinic Rochester, Rochester, ³Weill Cornell Medicine, New York, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Cardiovascular (CV) risk estimation across diverse rheumatoid arthritis (RA) cohorts may be challenging given potential heterogeneity in comorbidities and widely varying prevalence of CV…
Abstract Number: 1078 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study
Dionicio Angel Galarza-Delgado ¹, Iris Colunga-Pedraza ², Jose Azpiri-Lopez ², Karla Paola Cuellar-Calderon², Ileana Cecilia Reynosa-Silva ², Marielva Castro-Gonzalez ² and Carolina Marlene Martinez-Flores ², ¹Universidad Autonoma de Nuevo Leon "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ²Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Cardiovascular diseases are among the most common comorbidities in patients with rheumatic diseases (RD) and leads them to an overall increase of mortality in…
Abstract Number: 2323 • 2019 ACR/ARP Annual Meeting
The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Sicong Huang ¹, Zeling He ¹, Daniel Solomon ², Elena Massarotti ³, Charlotte Golnik ¹, Thany Seyok ¹, Seth Brownmiller ⁴, Tianrun Cai ³, Nicole Yang ³, Laurel Campbell ³, Leanne Barrett ³, Courtney Bibbo ³, Kenneth Pariser ³, Derrick Todd ³, Marcy Bolster ⁴, Marcelo Di Carli ³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: Inflammation accounts for much of the excess cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). We hypothesize that increased systemic inflammation leads to…
Abstract Number: 196 • 2019 ACR/ARP Annual Meeting
Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro ², Rebecca Schumacher ², Teresa Simon ³ and Kaleb Michaud ¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb*, Princeton, NJ
Background/Purpose: With the advent of JAK inhibitors has come increased concerns for the risk of venous thromboembolism (VTE), which was already known to be increased…
Abstract Number: 1095 • 2019 ACR/ARP Annual Meeting
The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis
Linh Truong¹, Nicole Ridolfi ², Eugenia Chen ² and Maida wong ³, ¹University of California, Irvine, San Diego, CA, ²University of California, Irvine, Orange, ³Tibor Rubin Veterans Affairs Medical Center, Long Beach
Background/Purpose: There is accumulating evidence demonstrating an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among the psoriatic arthritis (PsA) population. Yet, the relationship between immunosuppressive…
Abstract Number: 2326 • 2019 ACR/ARP Annual Meeting
Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
Annelies Blanken¹, Rabia Agca ², Conny van der Laken ³ and Mike Nurmohamed ⁴, ¹Amsterdam Rheumatology and immunulogy Center location Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center location Amsterdam UMC location VU medical center, Amsterdam, Netherlands Antilles, ⁴Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, explained both by an increased prevalence of traditional CV risk factors and…
Abstract Number: 261 • 2019 ACR/ARP Annual Meeting
Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample
Shraddha Jatwani¹, Karan Chugh ¹, Bikramjit Bindra ² and Karan Jatwani ³, ¹St. Vincent Evansville, Evansville, ²Government Medical College & Hospital, Chandigarh, India, ³Mount Sinai West - St Luke’s Hospital, New York
Background/Purpose: Atrial Fibrillation (AF) is a common cardiac arrhythmia related to increased cardiovascular morbidity and mortality. There is a significant association of systemic inflammation with…
Abstract Number: 1107 • 2019 ACR/ARP Annual Meeting
Are Rheumatologists Correctly Identifying and Controlling Traditional Cardiovascular Risk Factors?
Dionicio Galarza-Delgado ¹, Jose Azpiri-Lopez ¹, Iris Colunga-Pedraza ¹, Iván de Jesús Hernández-Galarza ¹, Ileana Cecilia Reynosa-Silva¹, Karla Paola Cuellar-Calderon ¹, Marielva Castro-Gonzalez ¹ and Carolina Marlene Martinez-Flores ¹, ¹Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Chronic systemic inflammation generated by rheumatic diseases (RD) is related to the increased cardiovascular risk (CVR) in this population. However, the coexistence of traditional…
Abstract Number: 2332 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients
Hafis Muhammed¹, Durga P Misra ¹, Sujata Ganguly ¹, Sarit Sekhar Pattanaik ¹, Saurabh Chaturvedi ¹, Harshit Singh ¹, Mohit K Rai ¹, Anamika Anuja ¹, Namita Mohindra ¹, Neeraj Jain ¹, Sudeep Kumar ¹ and Vikas Agarwal ¹, ¹SGPGI, Lucknow, Uttar Pradesh, India
Background/Purpose: Rheumatoid arthritis(RA) patients have increased cardiovascular(CV) risk with no data on CV risk scores in Indian patients.The primary objective was to study prevalence of…
Abstract Number: 279 • 2019 ACR/ARP Annual Meeting
Comparison of Carotid Ultrasound and Coronary Artery Calcium Score in Cardiovascular Risk Stratification of Patients with Inflammatory Rheumatic Diseases
Keith Colaco¹, Elsie Nguyen ², Shadi Akhtari ³, Paula Harvey ³ and Lihi Eder ⁴, ¹University of Toronto, Women's College Hospital, University Health Network, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: The value of non-invasive vascular imaging for cardiovascular (CV) risk stratification of patients with inflammatory rheumatic diseases is unclear. Measures of atherosclerosis including coronary…
Abstract Number: 1227 • 2019 ACR/ARP Annual Meeting
A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout
Daisy Vedder ¹, Martijn Gerritsen ¹, Mike Nurmohamed ², Ronald van Vollenhoven ³ and Christian Lood⁴, ¹Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴University of Washington, Seattle, WA
Background/Purpose: Patients with gout have an increased cardiovascular morbidity and mortality, not fully explained by traditional cardiovascular risk factors. Xanthine oxidase-induced oxidative stress, increased lipid…
Abstract Number: 2334 • 2019 ACR/ARP Annual Meeting
Is Cardiovascular Risk and Mortality in Rheumatoid Arthritis Compared to Diabetes Mellitus and the General Population Overestimated?
Brian Løgstrup¹, Torkell Ellingsen ², Alma Pedersen ³, Bianka Darvalics ³, Kevin Olesen ⁴, Hans Erik Bøtker ⁴ and Michael Mæng ⁴, ¹Department of Cardiology, Aarhus University Hospital, Denmark, Aarhus, Syddanmark, Denmark, ²Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁴Department of Cardiology, Aarhus University Hospital, Denmark, Aarhus, Denmark
Background/Purpose: To compare the risk of cardiovascular disease (CVD) and mortality in patients with rheumatoid arthritis (RA), diabetes mellitus (DM), and the general population.Methods: Patients…
Abstract Number: 316 • 2019 ACR/ARP Annual Meeting
Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA
Liliya Gandrabur¹, Woo Young Kim ¹, Aditi Sen ¹, Deana Nes ¹, Julia Ash ¹, Amy Wasserman ¹ and Kirk Sperber ¹, ¹Westchester Medical Center, Valhalla, NY
Background/Purpose: Evidence suggests that the tools used for cardiovascular disease (CVD) risk assessment in the general population underestimate the true risk when they are applied…
Abstract Number: 1344 • 2019 ACR/ARP Annual Meeting
Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study
Eric Toussirot¹, Hubert Marotte ², denis Mulleman ³, gregoire Cormier ⁴, fabienne Coury-Lucas ⁵, Philippe Gaudin ⁶, Emmanuelle Dernis ⁷, christine bonnet ⁸, richard damade ⁹, jean-luc Grauer ¹⁰, Tassadit Ait Abdesselam ¹¹, caroline Karras ¹², frederic Liote ¹³, Pascal Hilliquin ¹⁴, antoinette sacchi ¹⁵, Jean-Marie Berthelot ¹⁶, marc puyraveau ¹ and gilles dumoulin ¹, ¹University Hospital, Besancon, France, ²University Hospital, St Etienne, France, ³University hospital, Tours, France, ⁴CHD Vendée, La Roche sur Yon, France, ⁵University Hospital, Lyon, France, ⁶Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ⁷Rheumatology Department, Le Mans Central Hospital, Le Mans, France, ⁸University Hospital, Limoges, France, ⁹Centre Hospitalier, Chartres, France, ¹⁰Centre Hopsitalier, Montelimar, France, ¹¹Centre Hospitalier, Meaux, France, ¹²Hôpital Saint Joseph, Marseille, France, ¹³AP-HP, Paris, France, ¹⁴Centre Hospitalier, Corbeil Essones, France, ¹⁵Centre Hospitalier, Mantes la Jolie, France, ¹⁶University Hospital, Nantes, France
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) diseases. Dyslipidemia is a known adverse reaction to tocilizumab (TCZ). TNFa blockade…

1
2
3
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].